HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.

[1]  A. Guerrero,et al.  2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.

[2]  F. Raal,et al.  Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig) , 2016 .

[3]  A. Hutchings,et al.  Achievement of European atherosclerosis society (EAS) targets with lomitapide, a microsomal transfer protein inhibitor in homozygous familial hypercholesterolaemia (HoFH) , 2016 .

[4]  J. Min,et al.  Effects of Liver Transplantation on Lipids and Cardiovascular Disease in Children With Homozygous Familial Hypercholesterolemia. , 2016, The American journal of cardiology.

[5]  G. Watts,et al.  MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. , 2016, Journal of atherosclerosis and thrombosis.

[6]  F. Raal,et al.  Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. , 2016, Atherosclerosis.

[7]  I. Gouni-Berthold,et al.  Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review , 2016, Expert review of clinical pharmacology.

[8]  R. Santos.  Review: PCSK9 inhibitors reduce mortality but increase neurocognitive events in hypercholesterolemia , 2016, Annals of Internal Medicine.

[9]  Z. Fayad,et al.  LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. , 2016, Journal of clinical lipidology.

[10]  I. Mcdowell,et al.  Relationship between measurements of non-HDL-cholesterol and LDL-cholesterol in Familial Hypercholesterolaemia , 2016 .

[11]  H. Soran,et al.  Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. , 2015, European heart journal.

[12]  T. Aitman,et al.  Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. , 2015, Atherosclerosis.

[13]  H. Ginsberg,et al.  PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era , 2015, Current opinion in lipidology.

[14]  G. Watts,et al.  Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia , 2015, Drugs.

[15]  Rohit Kohli,et al.  Familial homozygous hypercholesterolemia: When to turn to transplant? , 2015, Pediatric transplantation.

[16]  S. Dehghani,et al.  Liver transplantation as a definitive treatment for familial hypercholesterolemia: A series of 36 cases , 2015, Pediatric transplantation.

[17]  J. E. Roeters van Lennep,et al.  Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. , 2015, Journal of clinical lipidology.

[18]  Biao Xu,et al.  Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials , 2015, BMC Medicine.

[19]  D. Gaudet,et al.  The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. , 2015, Atherosclerosis.

[20]  F. Bäckhed,et al.  Farnesoid X Receptor Inhibits Glucagon-Like Peptide-1 Production by Enteroendocrine L-cells , 2015, Nature Communications.

[21]  Carol Coupland,et al.  Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2015, BMJ : British Medical Journal.

[22]  V. Bláha,et al.  Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis. , 2015, Atherosclerosis Supplements.

[23]  G. Thompson.  Managing homozygous familial hypercholesterolaemia from cradle to grave. , 2015, Atherosclerosis. Supplements.

[24]  N. Wu,et al.  Update of Clinical Trials of Anti-PCSK9 Antibodies , 2015, Cardiovascular Drugs and Therapy.

[25]  R. Brook,et al.  Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.

[26]  E. Bruckert,et al.  Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia. , 2015, Atherosclerosis.

[27]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[28]  M. Charng,et al.  Clinical observations and treatment of pediatric homozygous familial hypercholesterolemia due to a low-density lipoprotein receptor defect. , 2015, Journal of clinical lipidology.

[29]  G. Francis,et al.  Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism , 2015, Front. Cell Dev. Biol..

[30]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[31]  M. Albisetti,et al.  Monitoring aspirin therapy in children after interventional cardiac catheterization: laboratory measures, dose response, and clinical outcomes , 2015, European Journal of Pediatrics.

[32]  J. Kastelein,et al.  Abstract 16531: Decreased Cardiovascular Events in Familial Hypercholesterolemic Patients Treated With Mipomersen, an Antisense Inhibitor of Apolipoprotein B Translation , 2014 .

[33]  F. Kronenberg,et al.  Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. , 2014, Journal of the American College of Cardiology.

[34]  D. Blom,et al.  Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. , 2014, Atherosclerosis. Supplements.

[35]  J. Mckenney,et al.  Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). , 2014, The American journal of cardiology.

[36]  J. Borén,et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society , 2014, European heart journal.

[37]  Kees Hovingh,et al.  Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. , 2014, Atherosclerosis.

[38]  S. Humphries,et al.  Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations , 2014, Journal of Medical Genetics.

[39]  P. Barter,et al.  Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. , 2014, Journal of the American College of Cardiology.

[40]  P. Pellikka,et al.  Stress echo applications beyond coronary artery disease. , 2014, European heart journal.

[41]  R. Giugliano,et al.  Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[42]  Jbs Board.  Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[43]  D. Rader,et al.  Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. , 2014, Circulation.

[44]  A. Garg,et al.  Sitosterolemia presenting with severe hypercholesterolemia and intertriginous xanthomas in a breastfed infant: case report and brief review. , 2014, The Journal of clinical endocrinology and metabolism.

[45]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[46]  R. Santos,et al.  Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension , 2013, European heart journal.

[47]  S. Bornstein,et al.  Lipoprotein apheresis: an update , 2013 .

[48]  J. de Graaf,et al.  ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management , 2013, Critical reviews in clinical laboratory sciences.

[49]  G. Thompson,et al.  Lipoprotein apheresis for the treatment of familial hypercholesterolemia , 2013 .

[50]  F. Raal,et al.  Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia , 2013, Circulation.

[51]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[52]  Sonia Shah,et al.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.

[53]  D. Gaudet,et al.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[54]  G. Watts,et al.  Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia , 2012, Vascular health and risk management.

[55]  A. Burroughs,et al.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). , 2012, Journal of hepatology.

[56]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[57]  K. Arnesen,et al.  Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. , 2012, Journal of clinical lipidology.

[58]  M. Yacoub,et al.  Translational Lessons from a Case of Combined Heart and Liver Transplantation for Familial Hypercholesterolemia 20 Years Post-operatively , 2012, Journal of Cardiovascular Translational Research.

[59]  R. Schiel,et al.  LDL-Apheresis: Technical and Clinical Aspects , 2012, TheScientificWorldJournal.

[60]  C. Town,et al.  Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy , 2011, Circulation.

[61]  H. Soran,et al.  Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients , 2011, Annals of clinical biochemistry.

[62]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[63]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[64]  Jeroen F. J. Laros,et al.  LOVD v.2.0: the next generation in gene variant databases , 2011, Human mutation.

[65]  Küçükkartallar Tevfik,et al.  Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia , 2011 .

[66]  J. Kastelein,et al.  Molecular Basis of Autosomal Dominant Hypercholesterolemia: Assessment in a Large Cohort of Hypercholesterolemic Children , 2011, Circulation.

[67]  James Jeffrey Malatack, MD.  Liver transplantation as treatment for familial homozygous hypercholesterolemia: Too early or too late , 2011, Pediatric transplantation.

[68]  B. Paulweber,et al.  Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe , 2010, Current opinion in lipidology.

[69]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[70]  A. Munnich,et al.  Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France , 2010, Human mutation.

[71]  V. Nobili,et al.  Preemptive liver transplantation in a child with familial hypercholesterolemia , 2010, Pediatric transplantation.

[72]  D. Gaudet,et al.  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[73]  J. Newburger,et al.  Antiplatelet Therapy in Pediatric Cardiovascular Patients , 2010, Pediatric Cardiology.

[74]  A. Marais,et al.  Efficacy criteria and cholesterol targets for LDL apheresis. , 2010, Atherosclerosis.

[75]  S. Bornstein,et al.  The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption. , 2009, Atherosclerosis. Supplements.

[76]  C. Keller.  LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. , 2009, Atherosclerosis. Supplements.

[77]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[78]  H. Borberg.  26 years of LDL--apheresis: a review of experience. , 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[79]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[80]  J. Goldstein,et al.  The LDL receptor. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[81]  D. Rader,et al.  Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. , 2008, The American journal of cardiology.

[82]  J. Rosenstock,et al.  Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy , 2008, Diabetes Care.

[83]  F. Kirkham,et al.  Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[84]  J. Schlienger,et al.  Low‐density Lipoprotein Apheresis in Children With Familial Hypercholesterolemia: Follow‐up to 21 Years , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[85]  D. Rader,et al.  A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. , 2008, Atherosclerosis.

[86]  H. Schlitt,et al.  Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL‐receptor gene mutation , 2007, Clinical transplantation.

[87]  S. Oikawa,et al.  Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. , 2007, Journal of atherosclerosis and thrombosis.

[88]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[89]  M. D. Di Carli,et al.  New technology for noninvasive evaluation of coronary artery disease. , 2007, Circulation.

[90]  Y. Akamatsu,et al.  Two cases in one family of living donor liver transplantation for homozygous familial hypercholesterolemia , 2006, Journal of Gastroenterology.

[91]  Hyesung Jeon,et al.  Structure and physiologic function of the low-density lipoprotein receptor. , 2005, Annual review of biochemistry.

[92]  N. Heaton,et al.  Successful living-related liver transplantation for familial hypercholesterolemia in the Middle East , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[93]  P. Monagle,et al.  Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[94]  F. Dati,et al.  First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B , 2004, Clinical chemistry and laboratory medicine.

[95]  Jonathan D. Cohen,et al.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.

[96]  N. Ohkohchi,et al.  Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia , 2003, Transplant international : official journal of the European Society for Organ Transplantation.

[97]  E. Sijbrands,et al.  Low-Density Lipoprotein Receptor Gene Mutations and Cardiovascular Risk in a Large Genetic Cascade Screening Population , 2002, Circulation.

[98]  P. Kovacs.  The risk of cardiovascular disease with second- and third-generation oral contraceptives. , 2002, Medscape women's health.

[99]  D. Gaudet,et al.  Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia , 2002, Circulation.

[100]  M. V. van’t Hof,et al.  The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. , 2000, Atherosclerosis.

[101]  F. Raal,et al.  Lipoprotein(a) in homozygous familial hypercholesterolemia. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[102]  P. Demacker,et al.  The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability. , 1999, Atherosclerosis.

[103]  A. Gotto,et al.  Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. , 1999, Circulation.

[104]  Clare,et al.  Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. , 1997, Journal of lipid research.

[105]  P. Nihoyannopoulos,et al.  Aortic stenosis in homozygous familial hypercholesterolaemia. , 1996, Heart.

[106]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[107]  H. Hobbs,et al.  The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. , 1990, Annual review of genetics.

[108]  F. Reeves,et al.  Long term follow-up after portacaval shunt and internal mammary coronary bypass graft in homozygous familial hypercholesterolemia: report of two cases. , 1990, The Canadian journal of cardiology.

[109]  J. Breslow,et al.  Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. , 1985, British medical journal.

[110]  T. Chattopadhyay,et al.  Treatment of homozygous familial hypercholesterolaemia. , 1985, British medical journal.

[111]  C. E. Becker.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[112]  M. Forman,et al.  Treatment of homozygous familial hypercholesterolaemia with portacaval shunt. , 1982, Atherosclerosis.

[113]  A. Soutar,et al.  Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[114]  L. Tokgozoglu,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2017, Revista Española de Cardiología.

[115]  J. Neuberger.  An update on liver transplantation: A critical review. , 2016, Journal of autoimmunity.

[116]  L. Hemphill,et al.  Lipoprotein Apheresis. , 2016, Endocrinology and metabolism clinics of North America.

[117]  John Adams.  NHS Blood and Transplant. , 2015, Nursing Standard.

[118]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2015 .

[119]  G. Thompson,et al.  Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances , 2014, Current Atherosclerosis Reports.

[120]  B. Vaidyanathan,et al.  Anti-platelet agents in pediatric cardiac practice , 2013, Annals of pediatric cardiology.

[121]  M. Taskinen,et al.  ESC/EAS Guidelines for the Management of Dyslipidaemias , 2013 .

[122]  T. Küçükkartallar,et al.  Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia. , 2011, Pediatric transplantation.

[123]  B. J. Gersh.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .

[124]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[125]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[126]  The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.